Physician profile
Adnan Haider
NPI 1689871899
$2,570.93
in general payments reported to CMS, 2019-2025
28 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $198 · 2021: $230 · 2022: $252 · 2023: $280 · 2024: $424 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456 · Honoraria: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.03 |
| Honoraria | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $489.41 | 2019-2025 | Ozempic, Rybelsus |
| Chiesi USA, INC. | $325.00 | 2025 | Mycapssa |
| Medtronic, INC. | $299.22 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $190.67 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $189.26 | 2020-2025 | Omnipod |
| Lilly USA, LLC | $167.11 | 2019-2022 | |
| Abbott Laboratories | $143.20 | 2021-2025 | Freestyle Libre 3 |
| Kiniksa Pharmaceuticals International, Plc | $81.34 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $80.85 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.10 | 2020-2022 | |
| Cequr Corporation | $72.44 | 2023-2024 | Cequr Simplicity |
| Eisai INC. | $59.46 | 2024-2025 | |
| Amgen INC. | $56.09 | 2020-2025 | Prolia, Evenity, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $52.17 | 2024-2025 | |
| Sequel Med Tech, LLC | $43.69 | 2025 | Twiist |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $26.83 | 2022-2023 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $25.32 | 2025 | |
| Pfizer INC. | $24.04 | 2025 | |
| Ascendis Pharma Endocrinology INC | $22.68 | 2023 | |
| Medtronic Minimed, INC. | $22.30 | 2020 | |
| Nevro Corp. | $21.37 | 2023 | Senza |
| Shire North American Group INC | $19.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.85 | 2022 | |
| Tandem Diabetes Care, INC. | $15.36 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $15.33 | 2023 | |
| Radius Health, INC. | $14.26 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.99 | 2025 | |
| Beta Bionics, INC. | $7.43 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.